BioNTech SE

🌍 Celebrating 5 Years on Nasdaq & BioNTech Innovation Day 2024 🌟 This week marked a special milestone for BioNTech as we celebrated five years on the #Nasdaq market! On that special occasion, our CEO and Co-Founder, Ugur Sahin, rang the Nasdaq Opening Bell. This highlights our decade and a half of efforts to advance science into survival as we continue driving research and development in combination with our investigational mRNA vaccines, targeted therapies, and immunomodulators. In addition to celebrating this Nasdaq milestone, we hosted #InnovationDay2024, bringing our leadership together to present updates on our corporate strategy, commercial strategy and clinical progress across our pipeline of groundbreaking cancer and infectious disease advancements. The event serves as a testament to our continuous dedication to advancing science in ways that can potentially transform healthcare and improve patient outcomes around the world. #ImmunoOncology

+++ 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐎𝐮𝐫 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲: 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐁𝐢𝐨𝐭𝐡𝐞𝐮𝐬, 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥+++ 🚀 Today, we are taking another step toward becoming a commercial-stage oncology company as we announce the signing of a definitive agreement for the acquisition of Biotheus Inc.. 🌍 The planned acquisition will support the global execution of our oncology strategy by strengthening one of its three key pillars: our next-generation immuno-modulator capabilities.  Today’s agreement builds on our successful ongoing collaboration with Biotheus, including the development of one of our key assets: BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody. 🔬 Complementing our investigational mRNA-based cancer vaccines and targeted therapies, BNT327/PM8002 has the potential to become a next-generation immuno-oncology backbone in our oncology pipeline, aimed at improving outcomes in patients with solid tumors. 🗓️ 𝐒𝐨𝐮𝐧𝐝 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐢𝐧𝐠? Tune into our 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐑&𝐃 𝐃𝐚𝐲 𝐨𝐧 𝟏𝟒 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 and hear about additional details on the transaction and our path towards unlocking the next wave of innovative treatment in oncology. Link to PR and forward-looking statements disclaimer: https://lnkd.in/eNbhzbH2 #BioNTech #OncologyRevolution #CancerTherapy #HealthcareInnovation #Biotech

🎗 BioNTech's Q3 Updates 🔬 Our commitment to advancing investigational cancer therapies continues as we progress several key candidates toward the pivotal stage. 🚀 Together with our partner Pfizer, we launched two variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season in multiple regions, leading to a financially strong third quarter. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/eH_3mU8a

Curious about how AI shapes our work and may contribute to the development of next-gen immunotherapies? 👩🔬 At our 𝐀𝐈 𝐃𝐚𝐲 𝟐𝟎𝟐𝟒, we introduced some of the amazing things we at BioNTech and InstaDeep are working on, such as 🔬how we use AI-enhanced computer vision to analyze patients’ tumor tissue 🧬how we use AI models to functionally understand patients’ DNA better with the aim of providing targeted immunotherapies 🧫how we use AI to generate potentially novel antibodies and combine AI with analytical methods with the aim of discovering new therapeutic targets A replay of the webcast will be available on BioNTech’s website.

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐄𝐒𝐌𝐎 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟒 We look forward to presenting updates for selected assets of our diversified immuno-oncology portfolio at the ESMO - European Society for Medical Oncology Congress 2024 in Barcelona. This year’s presentations feature programs across our multi-platform #oncology toolkit, including #mRNA-based cancer vaccines, targeted therapy approaches such as CAR-T cell therapies and ADCs, and next-generation #immunomodulators. We believe that the future of cancer treatment will be driven by the combination of modalities. Combination therapies have the potential to open up new opportunities through complementary or even synergistic mechanisms of action. Our goal is clear: Establish novel treatment paradigms to address the fundamental challenges of treating #cancer across all stages of the disease and improve outcomes for patients. 🚀 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 #𝐄𝐒𝐌𝐎𝟐𝟒. 👇 𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/etszNHB8

🎗 𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵'𝘀 𝗛𝟭 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 📣 We are advancing our oncology pipeline with mRNA as the centerpiece of our toolbox. In the first half of 2024, we presented encouraging data from our investigational mRNA-based cancer therapies, including BNT111 and BNT122. Additionally, we have progressed the development of immunomodulatory candidates, such as BNT327, which we believe are well-suited for combination therapies. We have continued to execute our combination therapy strategy by successfully initiating a trial evaluating the antibody candidate BNT327 in combination with the investigational ADC BNT325. 🌟🧬 More news from H1/2024 in our PR (incl. forward-looking statements): https://lnkd.in/edJXDHc9 #BioNTech #mRNA #CancerTherapy #Oncology

🔬𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: 𝐅𝐢𝐱𝐕𝐚𝐜 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐫𝐞𝐚𝐜𝐡𝐞𝐬 𝐦𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐢𝐧 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐭𝐫𝐢𝐚𝐥 At BioNTech, we envisioned personalized cancer medicine over 20 years ago and have started to develop novel precision tools. #mRNA is still today one of the center pieces in our toolbox that our researchers pioneered. Our goal remains unchanged: We want to establish mRNA as a new class of therapeutics to help address treatment challenges in oncology. 𝐓𝐨𝐝𝐚𝐲, 𝐰𝐞 𝐚𝐫𝐞 𝐚 𝐬𝐭𝐞𝐩 𝐜𝐥𝐨𝐬𝐞𝐫 𝐭𝐨 𝐚𝐜𝐡𝐢𝐞𝐯𝐢𝐧𝐠 𝐨𝐮𝐫 𝐯𝐢𝐬𝐢𝐨𝐧. Our personalized mRNA cancer treatment candidate BNT111, which is based on our FixVac platform, met its primary endpoint in combination with the PD-1 checkpoint inhibitor cemiplimab, developed by our partner Regeneron, in a randomized Phase 2 trial. The data demonstrated a statistically significant improvement in overall response rate in patients with advanced, hard-to-treat #melanoma. The #FixVac platform is one of our proprietary key mRNA cancer vaccine platforms, which is designed to target specific cancer indications by encoding a fixed set of antigens. They were identified to be frequently expressed on tumors of the same type – in this case BNT111 encodes four melanoma-associated antigens. The aim of our FixVac approach is to provide a personalized indication-specific, off-the-shelf therapy for cancer patients, particularly those with advanced, hard-to-treat disease where the medical need is still high in various indications.

🚣♂️🧑🏾🔬💚 𝐖𝐞'𝐫𝐞 𝐩𝐫𝐨𝐮𝐝 𝐭𝐨 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐢𝐧𝐜𝐫𝐞𝐝𝐢𝐛𝐥𝐞 𝐑𝐨𝐰𝐢𝐧𝐠 𝐀𝐠𝐚𝐢𝐧𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐞𝐯𝐞𝐧𝐭 𝐢𝐧 𝐌𝐚𝐢𝐧𝐳, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲! 🚣♀️🧑🏾🔬💚 Rowing is a sport that perfectly exemplifies the power of collaboration, and we were honored to join patients, doctors, professional athletes, companies, and all other participants at this annual benefit. The event, a proud tradition since 2005, aims to provide cancer patients with medically supervised sports and movement therapies. 272 passionate rowers came together to form 68 teams, uniting for a common cause. We are especially proud of the 40 BioNTech pioneers who have joined the event in 10 teams, showcasing our commitment to fighting cancer beyond the lab. Together, we rowed, we supported, and we made a difference. Thank you to everyone who participated and supported this amazing cause! 💪#RowingAgainstCancer #TeamBioNTech #StrongerTogether #CancerAwareness #MainzEvents

+++ 𝗢𝘂𝗿 𝗺𝗥𝗡𝗔 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗖𝗲𝗻𝘁𝗲𝗿 𝗶𝗻 𝗠𝗲𝗹𝗯𝗼𝘂𝗿𝗻𝗲 𝗵𝗮𝘀 𝗼𝗽𝗲𝗻𝗲𝗱 +++ 🚀 We are excited to contribute to strengthen one of the leading life sciences hubs in the Asia Pacific region with our mRNA Innovation Center in Melbourne. Based on our strategic partnership with the State of Victoria, we aim to support the development of the local mRNA ecosystem by working with researchers, start-ups and other third parties, helping them advance their mRNA research and provide scientific mentoring for a potential transition into preclinical and clinical development.    🔬 Our team of first movers and pioneering scientists has a proven track record of translating academic research into clinical development: Our experts have developed a clinical pipeline of innovative investigational immunotherapies and vaccines to address cancer, infectious diseases, and other serious diseases. We are looking forward to supporting the State of Victoria’s mRNA ecosystem with our expertise.    💡 Curious about other things we're currently working on in Australia with mRNA Victoria and La Trobe University?     Learn more: https://lnkd.in/eNCyGEUb     #BioNTech #innovation #technology #startup #Australia #Melbourne #mRNA #oncology      📸: La Trobe University 

+++ 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐍𝐞𝐰𝐬: 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐂𝐇𝐌𝐏 𝐨𝐩𝐢𝐧𝐢𝐨𝐧 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐚𝐝𝐚𝐩𝐭𝐞𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞+++ As we remain committed to providing COVID-19 vaccines that are matched to relevant circulating variants or sublineages, we are happy to announce that we and our partner Pfizer have received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for our monovalent Omicron JN.1-adapted #COVID19 Vaccine in the European Union.    The European Commission (EC) will review the CHMP’s recommendation and is expected to make a final decision soon. Following the EC decision, the updated vaccine will be available to ship to applicable EU member states immediately. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/e9sV7Qfn